Growth Dynamics on Rheumatoid Arthritis Therapeutics Market 2018-2025

Posted by Rushikesh Pise on December 3rd, 2019

Exhibiting a high prevalence for rheumatoid arthritis, North America is forecast to lead the global rheumatoid arthritis therapeutics market in a recent report. In a report, titled “RHEUMATOID ARTHRITIS THERAPEUTICS: GLOBAL MARKET ANALYSIS, INSIGHTS AND FORECAST, 2018-2025”, Fortune Business Insights identifies numerous factors enabling growth in the market. According to the report, the global rheumatoid arthritis therapeutics market is anticipated to exhibit 4.6% CAGR and reach valuation of US$ 33,958.4 Mn in 2025 from US$ 23,822.5 Mn in 2017.

Browse Complete Report:

https://www.fortunebusinessinsights.com/industry-reports/rheumatoid-arthritis-therapeutics-market-100488

Key players leading the global Rheumatoid Arthritis Therapeutics Marketinclude,

  •          Gilead Sciences
  •          Roche
  •          Eli Lilly and Company
  •          UCB
  •          Bristol-Myers Squibb
  •          Amgen
  •          Pfizer
  •          Celgene
  •         Johnson & Johnson

Notth America to Lead Global Market with Rising Prevalence of Rheumatoid Arthritis

The North America market was worth US$ 9,929.6 Mn in 2017. It is expected to show steady rise owing to the rising prevalence of rheumatoid arthritis and increasing awareness about this disorder. Adding to that, governments of North America are investing huge sums for improving the healthcare and medical facilities in the region. This is helping the rheumatoid arthritis therapeutics market to grow at an impressive pace in North America.

On the other side, the demand for rheumatoid arthritis treatment is likely to grow at a considerable pace in Asia Pacific. This is owing to the entry of new drugs, especially biologics, for the treatment of rheumatoid arthritis in the market. This, coupled with expansion of healthcare and medical infrastructure in emerging nations, is likely to help rheumatoid arthritis therapeutic market in Asia Pacific gain more momentum.

Biologics Segment to Account for Highest Market Share

In terms of product type, the biologics segment is anticipated to hold the highest share in the market in terms of revenue during the forecast period. In 2017, the biologics segment held 87.6% of the rheumatoid arthritis therapeutics market. This is because biologics targeting specific components of the immune response system help to slow down the rate of progression of arthritis in the patient. They also help in improving the physical functionality of patients and are cost efficient as compared to other treatment methods, which helps to increase the demand for biologics in the market.

 

Like it? Share it!


Rushikesh Pise

About the Author

Rushikesh Pise
Joined: November 4th, 2019
Articles Posted: 81

More by this author